Vyvgart gMG Label Expansion: Triple Seronegative Subtypes
An analysis of the May 2026 FDA label expansion for Vyvgart (efgartigimod) in generalized myasthenia gravis, covering triple seronegative subtypes and markets.
Back to Articles
Articles tagged with “argenx”